{
    "clinical_study": {
        "@rank": "142980", 
        "arm_group": {
            "arm_group_label": "Cohort"
        }, 
        "brief_summary": {
            "textblock": "This observational study will evaluate the efficacy and use of Mircera (methoxy polyethylene\n      glycol-epoetin beta) in patients with Stage V chronic kidney disease on haemodialysis\n      receiving an erythropoietin prior to study entry. Attending physicians should have made the\n      decision of placing the patient on Mircera in advance and not related to the study. The\n      therapy will be administered by the attendant treating physician according to specifications\n      in the package insert guidelines and to the routine of the site. Eligible patients will be\n      followed for 6 months."
        }, 
        "brief_title": "An Observational Study of Mircera (Methoxy Polyethylene Glycol-Epoetin Beta) in Stage V Chronic Kidney Disease Patients on Haemodialysis", 
        "completion_date": {
            "#text": "July 2010", 
            "@type": "Actual"
        }, 
        "condition": "Anemia", 
        "condition_browse": {
            "mesh_term": [
                "Anemia", 
                "Kidney Diseases", 
                "Renal Insufficiency, Chronic", 
                "Kidney Failure, Chronic"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Adult patients, >/= 18 years of age\n\n          -  Patients with chronic renal anemia with Stage V chronic kidney disease on dialysis\n             and with a Hb level of 10.0 - 13.0 g/dl\n\n          -  Patients must be receiving an ESA prior to entering study\n\n        Exclusion Criteria:\n\n          -  As per approved package insert\n\n          -  Any contraindication to ESA treatment"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "Patients with Stage V chronic kidney disease on haemodialysis with renal anemia receiving\n        an erythropoietin"
            }
        }, 
        "enrollment": {
            "#text": "89", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "September 9, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01940484", 
            "org_study_id": "ML22344"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 5, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Benoni", 
                        "country": "South Africa", 
                        "zip": "1501"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bloemfontein", 
                        "country": "South Africa", 
                        "zip": "9301"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cape Town", 
                        "country": "South Africa", 
                        "zip": "7925"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cape Town", 
                        "country": "South Africa", 
                        "zip": "7800"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Durban", 
                        "country": "South Africa"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Durban", 
                        "country": "South Africa", 
                        "zip": "4001"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Johannesburg", 
                        "country": "South Africa", 
                        "zip": "2157"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Johannesburg", 
                        "country": "South Africa", 
                        "zip": "1724"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Johannesburg", 
                        "country": "South Africa", 
                        "zip": "2193"
                    }
                }
            }
        ], 
        "location_countries": {
            "country": "South Africa"
        }, 
        "number_of_groups": "1", 
        "official_title": "An Observational, Non-interventional Cohort Study to Observe the Efficacy and Use of MIRCERA in the Treatment of Chronic Renal Anaemia in Patients With Chronic Kidney Disease Stage V on Haemodialysis", 
        "overall_official": {
            "affiliation": "Hoffmann-La Roche", 
            "last_name": "Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "South Africa: Medicines Control Council"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "July 2010", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Proportion of patients with Hb levels of 11-12 g/dl during the entire study period and at 4-6 months", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "measure": "Change in Hb levels", 
                "safety_issue": "No", 
                "time_frame": "from baseline to Month 6"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01940484"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Mean Mircera dose during study and at Month 6", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "measure": "Dose adjustments/interruptions", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "measure": "Proportion of patients managed according to the EBPG and K/DOQI guidelines and Mircera PI prior to and during Mircera treatment", 
                "safety_issue": "No", 
                "time_frame": "9 months"
            }, 
            {
                "measure": "Clinical/demographic patient characteristics at initiation of treatment", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }
        ], 
        "source": "Hoffmann-La Roche", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hoffmann-La Roche", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2009", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "May 2014"
    }
}